A Phase I/II Trial of CHOEP Chemotherapy plus Lenalidomide as Front Line Therapy for Patients with Stage II, III and IV Peripheral T-Cell Non-Hodgkin's Lymphoma
The purpose of this study is to find the best dose of the drug lenalidomide to give together with combination chemotherapy (cyclophosphamide, doxorubicin, vincristine, and etoposide, or CHOEP) in patients newly diagnosed with stage II-IV peripheral T-cell non-Hodgkin lymphoma.
Lenalidomide is already used to treat other cancers; its use in this study is considered investigational. It blocks the growth of the blood vessels that tumors need to grow. Adding lenalidomide to combination chemotherapy may enhance the effectiveness of treatment for fighting peripheral T-cell lymphoma.
Lenalidomide is taken orally (by mouth), while the combination chemotherapy is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have newly diagnosed stage II-IV peripheral T-cell lymphoma.
- Patients may have had prior radiation therapy and no more than one prior cycle of chemotherapy.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Steven M. Horwitz at 212-639-3045.